Saturday 27 July 2019

N ROP X NEUROCOGN OUTCOME

ROP treatment modality was not associated with differences in death or NDI, but the bevacizumab group had higher mortality and poor cognitive outcomes in early childhood. These data reveal the need for a rigorous appraisal of ROP therapy.

No comments:

Post a Comment